In summary, we systematically analyzed the expression, prognosis, mutations, and their relationship with cancer grades of different TRIM family members in glioma patients through bioinformatics method and determined that TRIM5, TRIM17, TRIM21, TRIM22, TRIM24, TRIM28, TRIM34 and TRIM47 molecules have a unique role in the development of glioma patients. This evidence concerns the gene TRIM17 and central nervous system cancer.